Skip to search formSkip to main contentSkip to account menu

CLARISCAN

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

ferumoxtran-10

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
Intravascular contrast agent-enhanced MRI measuring contrast clearance and tumor blood volume and the effects of vascular modifiers in an experimental tumor.
2002
2002
Multislice breath‐hold spiral magnetic resonance coronary angiography in patients with coronary artery disease: Effect of intravascular contrast medium
First, to apply a breath‐hold multislice 2D spiral magnetic resonance (MR) approach in patients acquiring within 16 heartbeats… 
2002
2002
Evaluation of a new ultrasmall superparamagnetic iron oxide contrast agent Clariscan®, (NC100150) for MRI of renal perfusion: Experimental study in an animal model
To determine the diagnostic value of a new ultrasmall superparamagnetic iron oxide Clariscan®, (NC100150) for the evaluation of… 
2002
2002
Three types of physical measurements needed to characterize iron oxide nanoparticles for MRI and MRA: magnetization, relaxometry, and light scattering.
2002
2002
Vasodilator Response Assessment in Porcine Myocardium With Magnetic Resonance Relaxometry
Background—This research describes an early preclinical study of the biophysical mechanisms governing changes in myocardial T2… 
2001
2001
Pre-clinical results with Clariscan™ (NC100150 Injection); experience from different disease models
A superparamagnetic nanoparticle (NC100150 Injection) was investigated in two different animal models; renal perfusion in pigs… 
2001
2001
Improved cine cardiovascular magnetic resonance using Clariscan (NC100150 injection).
We evaluated the use of Clariscan 0.75, 2, and 5 mg Fe/kg body weight in six patients to determine optimal dosing for short… 
2000
2000
The intravascular contrast agent Clariscan™ (NC 100150 injection) for 3D MR coronary angiography in patients with coronary artery disease
4. ConclusionIn our experience ClariscanTM improves image quality, thus, increasing the visual length and improving the actual… 
2000
2000
Evaluation of nonperfused myocardial ischemia with MRI and an intravascular USPIO contrast agent in an ex vivo pig model
The ultrasmall superparamagnetic iron oxide (USPIO) preparation NC100150 Injection (Clariscan; Nycomed Imaging, Oslo, Norway) was… 
2000
2000
Deep venous thrombosis and consecutive pulmonary embolism as the first sign of an ovarian cancer: MR angiography using an intravascular contrast agent (CLARISCAN)
We describe a case of progressive deep venous thrombosis and chest pain studied by contrast‐enhanced magnetic resonance (MR… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)